Skip to main content

Table 2 Diagnostic accuracy variables of three rapid antigen tests, with different sampling methods. Values are percentages (95% confidence interval) unless stated otherwise

From: Detection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study

Analysis

Sampling method

No.

Prevalencea (%)

Sensitivity

Specificity

PPV

NPV

BD-Veritor System (Beckton Dickinson)

 Primary analysis

OP-N

1441

13.0

68.6 (61.5 to 75.2)

99.8 (99.4 to 100.0)

98.5 (94.6 to 99.8)

95.5 (94.2 to 96.6)

 Secondary (stratified) analysis

       

  Viral load above the cut-offc

OP-N

1441

10.1

85.6 (78.9 to 90.9)

99.5 (99.0 to 99.8)

95.4 (90.3 to 98.3)

98.4 (97.6 to 99.0)

  Symptoms present at samplingb

       

   Yes

OP-N

662

18.1

75.8 (67.2 to 83.2)

99.8 (99.0 to 100.0)

98.9 (94.1 to 100.0)

94.9 (92.8 to 96.6)

   No

OP-N

742

8.0

55.9 (42.4 to 68.8)

99.9 (99.2 to 100.0)

97.1 (84.7 to 99.9)

96.3 (94.7 to 97.6)

SD-Biosensor (Roche Diagnostics)

 Primary analysis

NP

1769

12.2

74.4 (68.0 to 80.1)

99.8 (99.4 to 100.0)

98.2 (94.7 to 99.6)

96.6 (95.6 to 97.4)

OP-N

1689

9.7

75.0 (67.7 to 81.4)

99.8 (99.4 to 100.0)

97.6 (93.2 to 99.5)

97.4 (96.5 to 98.1)

 Secondary (stratified) analysis

       

  Viral load above the cut-offc

NP

1769

10.3

87.9 (82.3 to 92.3)

99.8 (99.4 to 100.0)

98.2 (94.7 to 99.6)

98.6 (97.9 to 99.1)

OP-N

1689

8.3

83.7 (76.5 to 89.4)

99.5 (99.0 to 99.8)

93.7 (87.9 to 97.2)

98.5 (97.8 to 99.1)

  Symptoms present at samplingb

       

   Yes

NP

1091

13.8

83.4 (76.5 to 89.0)

99.8 (99.2 to 100.0)

98.4 (94.5 to 99.8)

97.4 (96.2 to 98.3)

OP-N

900

12.7

78.9 (70.3 to 86.0)

99.7 (99.1 to 100.0)

97.8 (92.4 to 99.7)

97.0 (95.6 to 98.1)

   No

NP

658

9.6

54.0 (40.9 to 66.6)

99.8 (99.1 to 100.0)

97.1 (85.1 to 99.9)

95.3 (93.4 to 96.9)

OP-N

735

6.3

63.0 (47.5 to 76.8)

100.0 (99.5 to 100.0)

100.0 (88.1 to 100.0)

97.6 (96.2 to 98.6)

PanBio (Abbott)

 Primary analysis

NP

2056

8.4

68.8 (61.3 to 75.6)

99.9 (99.7 to 100.0)

99.2 (95.4 to 100.0)

97.2 (96.4 to 97.9)

 Secondary (stratified) analysis:

       

  Viral load above the cut-offcd

NP

2039

5.9

89.3 (82.3 to 94.2)

99.9 (99.6 to 100.0)

98.2 (93.6 to 99.8)

99.3 (98.9 to 99.6)

  Symptoms present at samplingb

       

   Yes

NP

1470

9.0

72.2 (63.7 to 79.6)

99.9 (99.6 to 100.0)

99.0 (94.4 to 100.0)

97.3 (96.3 to 98.1)

   No

NP

511

6.7

55.9 (37.9 to 72.8)

100.0 (99.2 to 100.0)

100.0 (82.4 to 100.0)

97.0 (95.0 to 98.3)

  1. NC not calculated because all Ag-RDT results were negative, NP deep nasopharyngeal, OP-N combined oropharyngeal and nasal sampling, PPV positive predictive value, NPV negative predictive value
  2. aSARS-CoV-2 infection based on the molecular test result
  3. bSymptoms not available for 37, 20, 53, and 75 participants, including 9, 1, 4, and 7 with a positive molecular test result, in the BD-Veritor group, SD-Biosensor NP group, SD-Biosensor OP-N group, and PanBio NP group, respectively
  4. cThe viral load cut-off was 5.2 log10 SARS-CoV-2 E-gene copies/mL. This was the viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture in a recent study by our group [6]
  5. dViral load unavailable for 17 participants in the PanBio NP group